Cargando…

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partne...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy, György, Roodenrijs, Nadia M T, Welsing, Paco M J, Kedves, Melinda, Hamar, Attila, van der Goes, Marlies C, Kent, Alison, Bakkers, Margot, Pchelnikova, Polina, Blaas, Etienne, Senolt, Ladislav, Szekanecz, Zoltan, Choy, Ernest H, Dougados, Maxime, Jacobs, Johannes WG, Geenen, Rinie, Bijlsma, Johannes WJ, Zink, Angela, Aletaha, Daniel, Schoneveld, Leonard, van Riel, Piet, Dumas, Sophie, Prior, Yeliz, Nikiphorou, Elena, Ferraccioli, Gianfranco, Schett, Georg, Hyrich, Kimme L, Mueller-Ladner, Ulf, Buch, Maya H, McInnes, Iain B, van der Heijde, Désirée, van Laar, Jacob M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761998/
https://www.ncbi.nlm.nih.gov/pubmed/34407926
http://dx.doi.org/10.1136/annrheumdis-2021-220973
_version_ 1784633662526980096
author Nagy, György
Roodenrijs, Nadia M T
Welsing, Paco M J
Kedves, Melinda
Hamar, Attila
van der Goes, Marlies C
Kent, Alison
Bakkers, Margot
Pchelnikova, Polina
Blaas, Etienne
Senolt, Ladislav
Szekanecz, Zoltan
Choy, Ernest H
Dougados, Maxime
Jacobs, Johannes WG
Geenen, Rinie
Bijlsma, Johannes WJ
Zink, Angela
Aletaha, Daniel
Schoneveld, Leonard
van Riel, Piet
Dumas, Sophie
Prior, Yeliz
Nikiphorou, Elena
Ferraccioli, Gianfranco
Schett, Georg
Hyrich, Kimme L
Mueller-Ladner, Ulf
Buch, Maya H
McInnes, Iain B
van der Heijde, Désirée
van Laar, Jacob M
author_facet Nagy, György
Roodenrijs, Nadia M T
Welsing, Paco M J
Kedves, Melinda
Hamar, Attila
van der Goes, Marlies C
Kent, Alison
Bakkers, Margot
Pchelnikova, Polina
Blaas, Etienne
Senolt, Ladislav
Szekanecz, Zoltan
Choy, Ernest H
Dougados, Maxime
Jacobs, Johannes WG
Geenen, Rinie
Bijlsma, Johannes WJ
Zink, Angela
Aletaha, Daniel
Schoneveld, Leonard
van Riel, Piet
Dumas, Sophie
Prior, Yeliz
Nikiphorou, Elena
Ferraccioli, Gianfranco
Schett, Georg
Hyrich, Kimme L
Mueller-Ladner, Ulf
Buch, Maya H
McInnes, Iain B
van der Heijde, Désirée
van Laar, Jacob M
author_sort Nagy, György
collection PubMed
description OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A–D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0–10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4–9.6). CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
format Online
Article
Text
id pubmed-8761998
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87619982022-01-26 EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis Nagy, György Roodenrijs, Nadia M T Welsing, Paco M J Kedves, Melinda Hamar, Attila van der Goes, Marlies C Kent, Alison Bakkers, Margot Pchelnikova, Polina Blaas, Etienne Senolt, Ladislav Szekanecz, Zoltan Choy, Ernest H Dougados, Maxime Jacobs, Johannes WG Geenen, Rinie Bijlsma, Johannes WJ Zink, Angela Aletaha, Daniel Schoneveld, Leonard van Riel, Piet Dumas, Sophie Prior, Yeliz Nikiphorou, Elena Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L Mueller-Ladner, Ulf Buch, Maya H McInnes, Iain B van der Heijde, Désirée van Laar, Jacob M Ann Rheum Dis Recommendation OBJECTIVE: To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid arthritis (D2T RA). METHODS: An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and non-pharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A–D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0–10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. RESULTS: Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4–9.6). CONCLUSIONS: These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research. BMJ Publishing Group 2022-01 2021-08-18 /pmc/articles/PMC8761998/ /pubmed/34407926 http://dx.doi.org/10.1136/annrheumdis-2021-220973 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Recommendation
Nagy, György
Roodenrijs, Nadia M T
Welsing, Paco M J
Kedves, Melinda
Hamar, Attila
van der Goes, Marlies C
Kent, Alison
Bakkers, Margot
Pchelnikova, Polina
Blaas, Etienne
Senolt, Ladislav
Szekanecz, Zoltan
Choy, Ernest H
Dougados, Maxime
Jacobs, Johannes WG
Geenen, Rinie
Bijlsma, Johannes WJ
Zink, Angela
Aletaha, Daniel
Schoneveld, Leonard
van Riel, Piet
Dumas, Sophie
Prior, Yeliz
Nikiphorou, Elena
Ferraccioli, Gianfranco
Schett, Georg
Hyrich, Kimme L
Mueller-Ladner, Ulf
Buch, Maya H
McInnes, Iain B
van der Heijde, Désirée
van Laar, Jacob M
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
title EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
title_full EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
title_fullStr EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
title_full_unstemmed EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
title_short EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
title_sort eular points to consider for the management of difficult-to-treat rheumatoid arthritis
topic Recommendation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761998/
https://www.ncbi.nlm.nih.gov/pubmed/34407926
http://dx.doi.org/10.1136/annrheumdis-2021-220973
work_keys_str_mv AT nagygyorgy eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT roodenrijsnadiamt eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT welsingpacomj eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT kedvesmelinda eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT hamarattila eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT vandergoesmarliesc eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT kentalison eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT bakkersmargot eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT pchelnikovapolina eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT blaasetienne eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT senoltladislav eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT szekaneczzoltan eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT choyernesth eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT dougadosmaxime eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT jacobsjohanneswg eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT geenenrinie eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT bijlsmajohanneswj eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT zinkangela eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT aletahadaniel eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT schoneveldleonard eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT vanrielpiet eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT dumassophie eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT prioryeliz eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT nikiphorouelena eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT ferraccioligianfranco eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT schettgeorg eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT hyrichkimmel eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT muellerladnerulf eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT buchmayah eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT mcinnesiainb eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT vanderheijdedesiree eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis
AT vanlaarjacobm eularpointstoconsiderforthemanagementofdifficulttotreatrheumatoidarthritis